Conclusion
In summary, HTx remains the treatment of choice for most EHF patients. Our patients’ postoperative complications, mortality, and survival rates coincided with those reported by the ISHLT registry. However, no survival adjustment was made according to postoperative complications or multivariate analysis of the profiles. The careful receptor and donor selection, advancement in immunosuppression protocol, and the early detection of postoperative complications have allowed us to perform HTx in our institution with acceptable results compared to others worldwide.